Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
SQNS Sequans and Huawei Collaborate to Advance LTE Broadcast Technology
4G chipmaker Sequans Communications S.A. (NYSE:SQNS) is collaborating with leading LTE infrastructure supplier, Huawei, to advance eMBMS (evolved multimedia broadcast multicast service) technology. eMBMS, also known as LTE Broadcast, is an advanced mobile data delivery technology that enables mobile operators to significantly reduce the cost of delivering high-bandwidth content such as video and audio to multiple users at one time over LTE networks.
Huawei and Sequans have conducted successful interoperability tests of eMBMS technology using Huawei’s LTE infrastructure equipment and end user devices based on Sequans’ eMBMS-capable LTE semiconductor solution. The two companies successfully demonstrated the delivery of live video and audio broadcast using both TDD and FDD and observed excellent performance during several testing sessions.
“LTE Broadcast will become vitally important to mobile operators in the very near future and we are pleased to collaborate with Sequans on advancing this important technology that will enable the delivery of new and exciting services to mobile users around the world,” said Timon Tian, President of MBB Video Solution, Huawei.
“Our LTE platform provides a robust eMBMS solution and our productive cooperation with Huawei demonstrates that our solution works end-to-end and is commercially viable,” said Georges Karam, Sequans CEO. “eMBMS technology enables excellent efficiency in delivering broadcast services over LTE networks, allowing mobile operators to maximize ARPU as never before.”
Sequans’ current LTE platforms support eMBMS as defined in 3GPP, including the enhancements specified for LTE-Advanced. Sequans’ eMBMS technology supports multiple concurrent sessions for multicast traffic along with unicast traffic on both TDD and FDD LTE networks. Sequans’ solution also provides a standardized interface to third-party eMBMS middleware.
The eMBMS testing with Huawei was done using Sequans’ Mont Blanc LTE platform. Mont Blanc is a member of Sequans’ StreamrichLTE™ product family for high performance mobile and portable LTE devices. It supports TDD and FDD for global compatibility and delivers category 4 throughput of 150 Mbps in the downlink.
Cautions regarding forward-looking statements
About Sequans Communications
Sequans Communications S.A. (NYSE:SQNS) is a 4G chipmaker, supplying LTE and WiMAX chips to original equipment manufacturers and original design manufacturers worldwide. Founded in 2003 to address the WiMAX market, the company expanded in early 2009 to address the LTE market. Sequans’ chips are today operating in 4G networks around the world. Sequans is based in Paris, France with additional offices throughout the world, including United States, United Kingdom, Israel, Hong Kong, Singapore, Taiwan, South Korea, and China. Visit Sequans online at www.sequans.com; www.facebook.com/sequans; www.twitter.com/sequans
Sequans Communications S.A.
Media Relations:
Kimberly Tassin, +1-425-736-0569
Kimberly@sequans.com
or
Investor Relations:
Claudia Gatlin, +1-212-830-9080
Claudia@sequans.com
Craig Hallum initiated coverage with BUY rating.
http://www.analystratings.net/stocks/NASDAQ/APPY/?RegistrationCode=SocialMedia-Twitter
PT taken from twitter, so no real source here.
"@johnhallnj: $MACK
ML:$6
Opp:$8.5
Mizu:$12
Gugg:$9
Brean:$16
JPM:$9
All 11/7 or later. EVA and Cowen no PT"
Brean Capital has a BUY rating and a $16.
http://www.breancapital.com/pdf/ResearchUniverse.pdf
put your money where your mouth is and short ROX and SQNS right now. i bet you won't. GL
i just have a $10.5 cost basis before RS. didn't buy any down here. didn't want to throw good money after bad. possibly bail if we see around $7 this week. i'm quite done with ECTE. GL
sometimes patiences pays back. GL
SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) (“Prima”, the “Company”) today announced that its Chief Executive Officer, Matthew Lehman, will present at the 11th Annual Commercial Translation of Regenerative Medicine meeting in London on November 25, 2013 at 1:55pm local time.
maybe that presentation was awesome...
impressive breakout today with high volume but no news as i didn't find some so far.
mgmt definitly could have done better. right now it's itching a bit that i didn't sell any shares when it was north of $2.60s.
SQNS 12.5M shares @$1.80 and the option to buy another 1.875M to cover overallotments.
i would've liked to see the offering @$2 and wonder about the $4M tax repay. curious how it will trade today.
maybe there will be another PR shortly after the offering containing another win or some sort of deal. hmmm.
boardvote.com/symbol/SQNS/communique/492619
i would consider ~40% of float short, an outlook about burning less cash than expected and to be break even by end of 2014 good fuel to light this puppy.
what i really like about their guidance despite their growing sales is that SUPN announced that they are expecting to burn lower cash for the full year 2013 ($70-75M) as previously anticipated ($85-95M).
during the nine month till 09/30 they already burned $69.9M and nonetheless they are narrowing their forecasts... is there something to happen in Q4?
imo, the "head" ain't got enough volume, so i see it as a break of a resistance zone ~$2 and lately the retest of the breakout zone with resistance now acting as support.
the gap you mentioned really looks like a breakaway gap (movement plus volume) and hence it doesn't need to be filled.
of course that's only my point of view.
ABIO $1.60 close HOD with impressive volume and +14% on a really weak market day.
watch out for possible gap up tomorrow and thereafter gap close @$2.30.
link back chart and DD
they pushed announcement of top-line data back from Q4 13 to Q1 14.
anyway, looks like we'll get some nice bargain prices again.
we got one failed trial with MAGE-A3, and thereafter 3 successful data announcements including malaria, herpes and glioblastoma and this stock doesn't move...??
at the current burn rate AGEN should be cash sufficient at least for six quarters (Q1 2015). float is still small with ~38M shares.
my guess: if the big boys are locked and loaded this baby will fly. my average is $3.15 and i'm willing to hold that puppy a little longer than i initially thought.
volume is impressive today with two trades over 1 million shares each. price lags so far. curious where it will close today.
we're getting near cash value. i'm waiting for the ER tomorrow to decide what to do next here.
the spread is amusing today. 33cents, then 18cents, now 20cents. looks like nobody is willing to sell below $7. depending on Q's data this could spark an enormous short squeeze.
again or just the dec calls you bought this summer?
TGTX told the story this week. panic selling on monday below $3 with no fundamental change. consolidation around $3.50-3.60. today the covering started and it closed $4.10.
got a terrible week with MACK, TGTX, ABIO and SGYP leading my portfolio downwards. know what you own is key here. sometimes you have to decide if you take the risk or bite the bullet and move on. for now, i tried the first one.
back in july the company had appproximately $210M after the offering. givin a burn rate of approximately $30M per quarter they now have around $170M.
O/S is 102M so cash value is ~$1.66 and enterprise value now is around 80c per share or $82M. ridiculous, imo.
nice pre market glitch. $21.14
APPY $1.84 some DD:
Q4 catalyst is close of enrollment of the pivotal study for APPY1 (blood-based appendicitis test) and filing for FDA clearance if the outcome is favorable in Q1 2014. The test already has a CE mark in europe and is available there.
Q2 CC:
http://seekingalpha.com/article/1550572-venaxis-inc-appy-ceo-hosts-second-quarter-2013-business-update-conference-transcript?source=yahoo
O/S is 21.45m, with ~5M shares institutional holding as of 07/11/2013.
http://whalewisdom.com/stock/appy
short position is 11,1% as of 10/15/2013
http://online.wsj.com/mdc/public/page/2_3062-shtnasdaq_V-listing.html
At the Close of the Q2 2013 the Company had $20M in cash and claims to be cash sufficient at least until reaching FDA clearance, though it filed a S-3 $20M common shelf 10/22/2013. revenue coming from sales in europe should bolster the financial Situation of Venaxis too.
Canaccord Genuity has a price target of $7.
http://seekingalpha.com/article/1486211-canaccord-genuity-sees-strong-upside-in-venaxis-shares-and-set-a-7-price-target?source=yahoo
Aegis has a $3.50 Price target.
http://www.streetinsider.com/Analyst+Comments/Aegis+Maintains+Venaxis+%28APPY%29+at+Buy%2C+Cuts+PT+to+%243.50+Following+Recent+Offering/8614827.html
from a TA Point of view APPY has a strong $1.80 Support and is preparing for the next leg up, that should bring it at least around $2.80. golden cross just happend on the daily chart and FullSto, RSI and MACD have not rolled over yet, but are on the verge of doing so.
APPY $1.84 some DD:
Q4 catalyst is close of enrollment of the pivotal study for APPY1 (blood-based appendicitis test) and filing for FDA clearance if the outcome is favorable in Q1 2014. The test already has a CE mark in europe and is available there.
Q2 CC:
http://seekingalpha.com/article/1550572-venaxis-inc-appy-ceo-hosts-second-quarter-2013-business-update-conference-transcript?source=yahoo
O/S is 21.45m, with ~5M shares institutional holding as of 07/11/2013.
http://whalewisdom.com/stock/appy
short position is 11,1% as of 10/15/2013
http://online.wsj.com/mdc/public/page/2_3062-shtnasdaq_V-listing.html
At the Close of the Q2 2013 the Company had $20M in cash and claims to be cash sufficient at least until reaching FDA clearance, though it filed a S-3 $20M common shelf 10/22/2013. revenue coming from sales in europe should bolster the financial Situation of Venaxis too.
Canaccord Genuity has a price target of $7.
http://seekingalpha.com/article/1486211-canaccord-genuity-sees-strong-upside-in-venaxis-shares-and-set-a-7-price-target?source=yahoo
Aegis has a $3.50 Price target.
http://www.streetinsider.com/Analyst+Comments/Aegis+Maintains+Venaxis+%28APPY%29+at+Buy%2C+Cuts+PT+to+%243.50+Following+Recent+Offering/8614827.html
from a TA Point of view APPY has a strong $1.80 Support and is preparing for the next leg up, that should bring it at least around $2.80. golden cross just happend on the daily chart and FullSto, RSI and MACD have not rolled over yet, but are on the verge of doing so.
APPY $1.84 some DD:
Q4 catalyst is close of enrollment of the pivotal study for APPY1 (blood-based appendicitis test) and filing for FDA clearance if the outcome is favorable in Q1 2014. The test already has a CE mark in europe and is available there.
Q2 CC:
http://seekingalpha.com/article/1550572-venaxis-inc-appy-ceo-hosts-second-quarter-2013-business-update-conference-transcript?source=yahoo
O/S is 21.45m, with ~5M shares institutional holding as of 07/11/2013.
http://whalewisdom.com/stock/appy
short position is 11,1% as of 10/15/2013
http://online.wsj.com/mdc/public/page/2_3062-shtnasdaq_V-listing.html
At the Close of the Q2 2013 the Company had $20M in cash and claims to be cash sufficient at least until reaching FDA clearance, though it filed a S-3 $20M common shelf 10/22/2013. revenue coming from sales in europe should bolster the financial Situation of Venaxis too.
Canaccord Genuity has a price target of $7.
http://seekingalpha.com/article/1486211-canaccord-genuity-sees-strong-upside-in-venaxis-shares-and-set-a-7-price-target?source=yahoo
Aegis has a $3.50 Price target.
http://www.streetinsider.com/Analyst+Comments/Aegis+Maintains+Venaxis+%28APPY%29+at+Buy%2C+Cuts+PT+to+%243.50+Following+Recent+Offering/8614827.html
from a TA Point of view APPY has a strong $1.80 Support and is preparing for the next leg up, that should bring it at least around $2.80. golden cross just happend on the daily chart and FullSto, RSI and MACD have not rolled over yet, but are on the verge of doing so.
taken from the last Q earnings call:
"The interim review of this ovarian trial and our wild type non-small lung cancer trial suggested it was likely that the overall populations would not meet the primary study endpoints. This is in line with our expectations and our objectives to validate our diagnostic through the translational effort and the identification of subgroups who respond to MM-121 in those studies."
so, todays news is not really surprising, imo.
http://m.seekingalpha.com/article/1621082-merrimack-pharmaceuticals-ceo-discusses-q2-2013-results-earnings-call-transcript?part=single
SUPN $6.76 pm[/]
FBR Capital starts SUPN with outperform & PT $12
http://www.briefing.com/Investor/Calendars/Upgrades-Downgrades/Initiated/2013/10/30
FBR Capital starts SUPN with outperform and PT $12
http://www.briefing.com/Investor/Calendars/Upgrades-Downgrades/Initiated/2013/10/30
they're wrong indeed. the 52w-low was on the last trading day in august 2013 printing $0.4000.
short interest went up 122% from two weeks ago, representing 885k shares 11.2% of float.
http://online.wsj.com/mdc/public/page/2_3062-shtnasdaq_A-listing.html
there seems to be a huge overhang from their $1.60 offering. once this resistance is broken on high volume, this puppy really could fly.
yearly low is $0.40, so there's definitly room to go for both directions.
appriciate your thoughts. have a nice chunk of shares @$1.83 average. BOL
only thing, i thought WiMax to be a dead end and expected LTE related news. good news though
ABIO $1.60 huge volume pm, bc of news submitting an IND.
http://www.wikinvest.com/wikinvest/api.php?action=viewNews&aid=5313700&page=NASDAQ:ABIO&comments=0&format=html
maybe it's time to fill the gap
Sequans Communications (SQNS) Lower after In-Line Q3, But Lower Q4 Rev Outlook
Earlier, Sequans Communications (NYSE: SQNS) reported Q3 EPS of ($0.19), in-line with the analyst estimate of ($0.19). Revenue for the quarter came in at $4.1 million versus the consensus estimate of $4 million.
Sequans Communications sees Q4 2013 EPS of ($0.15)-($0.17), versus the consensus of ($0.16). Sequans Communications sees Q4 2013 revenue of $4.5-5.5 million, versus the consensus of $6.5 million.
http://www.wikinvest.com/wikinvest/api.php?action=viewNews&aid=5302927&page=NYSE:SQNS&comments=0&format=html
the takedown from the 7.30s to below $6 was on light volume and the short interest has grown to 5.18M shares or 37.4% of the float. ER on 11/13/13 will be a big day either way. if the results and most important the guidance is as good as i expect it to be, we'll really have some firworks here. just my 2 cents.